Sell-Side Analysts: 11 Stocks Rated "Buy" by Big Names

A sell-side analyst works for a brokerage to compose reports and forecast the markets for their clients. They typically focus on a specific industry and produce regular reports containing predictions on commodity prices and expected performance for a stock.

Main Street investors benefit from sell-side analyst reports since seasoned experts typically write them. Better yet, sell-side research as a whole outperforms (link opens PDF) that of buy-side. Investors place their faith in sell-side ratings because the reports are not tailored for a specific client, but to all the clients of the brokerage. The analyst and the firm's reputation can stand on the line with each "buy," "sell," or "hold" rating.

But be warned, every report produced by a sell-side analyst is called a "blanket recommendation" because they do not take into account the wants and needs of every individual. Investors must therefore determine if they are applicable to their own portfolio.

And don't forget, the analyst is paid by the brokerage, not the clients themselves, so the report could be part of an agenda of the firm that you don't know about. So remember to measure twice and cut once because their reports do not necessarily provide proper advice for an individual investor.

Business section: Investing ideas
We gathered the sell-side analyst ratings from reputable firms including Argus, Barclays, Canaccord Genuity, Collins Stewart, Deutsche, Needham, Oppenheimer, Robert W Baird, UBS, and Wedbush.

We then screened for the stocks that had "buy," "outperform," or "overweight" ratings from at least three of those names. Eleven stocks made the cut. We list them below.

What do you think? Are sell-side analysts making the right call with these names? (Click here to access free, interactive tools to analyze these ideas.)

List by Rebecca Lipman:

1. Aegerion Pharmaceuticals: Engages in the development and commercialization of novel therapeutics to treat severe lipid disorders. Market cap at $301.31M, most recent closing price at $14.41. On 11/09/2011, Deutsche Bank had a Buy rating on the stock. On 05/22/2012, Needham had a Buy rating on the stock. On 03/26/2012, Canaccord Genuity had a Buy rating on the stock.

2. Allstate: Engages in the personal property and casualty insurance, life insurance, retirement, and investment products businesses primarily in the United States. Market cap at $16.25B, most recent closing price at $33.07. On 12/02/2011, Deutsche Bank had a Buy rating on the stock. On 08/10/2011, UBS had a Buy rating on the stock. On 03/05/2012, Argus had a Buy rating on the stock.

3. Alexion Pharmaceuticals: Engages in the discovery, development, and commercialization of biologic therapeutic products in the United States, Europe, Latin America, Japan, and the Asia Pacific. Market cap at $16.83B, most recent closing price at $87.60. On 12/09/2011, Barclays Capital had an Overweight rating on the stock. On 03/26/2012, Canaccord Genuity had a Buy rating on the stock. On 02/23/2012, UBS had a Buy rating on the stock. On 02/10/2012, Robert W. Baird had an Outperform rating on the stock.

4. Biogen Idec: Develops, manufactures, and markets therapeutics in the areas of neurology, immunology, hemophilia, and oncology in the United States and internationally. Market cap at $30.36B, most recent closing price at $126.73. On 12/09/2011, Barclays Capital had an Overweight rating on the stock. On 09/09/2011, UBS had a Buy rating on the stock. On 08/18/2011, Oppenheimer had an Outperform rating on the stock. On 06/21/2011, Deutsche Bank had a Buy rating on the stock.

5. Broadcom (Nasdaq: BRCM  ) : Designs and develops semiconductors for wired and wireless communications. Market cap at $17.49B, most recent closing price at $31.74. On 10/13/2011, Robert W. Baird had an Outperform rating on the stock. On 02/02/2012, Canaccord Genuity had a Buy rating on the stock. On 01/09/2012, Deutsche Bank had a Buy rating on the stock.

6. Salesforce.com (NYSE: CRM  ) : Provides customer and collaboration relationship management (CRM) services to various businesses and industries worldwide. Market cap at $18.08B, most recent closing price at $130.99. On 12/06/2011, Barclays Capital had an Overweight rating on the stock. On 11/28/2011, Needham had a Buy rating on the stock. On 05/25/2012, Oppenheimer had an Outperform rating on the stock.

7. Cisco Systems (Nasdaq: CSCO  ) : Designs, manufactures, and sells Internet protocol (IP)-based networking and other products related to the communications and information technology industry worldwide. Market cap at $85.5B, most recent closing price at $15.96. On 10/27/2011, UBS had a Buy rating on the stock. On 12/06/2011, Barclays Capital had an Overweight rating on the stock. On 05/09/2012, Needham had a Buy rating on the stock.

8. Cognizant Technology Solutions: Provides information technology consulting and technology services in North America, Europe, and Asia. Market cap at $17.33B, most recent closing price at $56.90. On 10/07/2011, Deutsche Bank had a Buy rating on the stock. On 05/08/2012, Robert W. Baird had a Outperform rating on the stock. On 05/07/2012, Needham had a Buy rating on the stock.

9. LinkedIn (Nasdaq: LNKD  ) : Operates an online professional network. Market cap at $9.45B, most recent closing price at $91.51. On 12/29/2011, Collins Stewart had a Buy rating on the stock. On 12/07/2011, Canaccord Genuity had a Buy rating on the stock. On 09/16/2011, Barclays Capital had an Overweight rating on the stock.

10. Ardea Biosciences: Focuses on the discovery and development of small-molecule therapeutics for the treatment of gout and cancer in the United States. Market cap at $1.18B, most recent closing price at $31.90. On 04/12/2012, UBS had a Buy rating on the stock. On 03/26/2012, Canaccord Genuity had a Buy rating on the stock. On 01/19/2012, Collins Stewart had a Buy rating on the stock.

11. Under Armour (NYSE: UA  ) : Designs, develops, markets, and distributes a range of apparel and accessories using synthetic microfiber fabrications in the U. Market cap at $4.99B, most recent closing price at $95.75. On 09/23/2011, Argus had a Buy rating on the stock. On 05/09/2012, UBS had a Buy rating on the stock. On 01/31/2012, Needham had a Buy rating on the stock. On 01/03/2012, Robert W. Baird had an Outperform rating on the stock.

Interactive Chart: Press Play to compare changes in analyst ratings over the last two years for the stocks mentioned above. Analyst ratings sourced from Zacks Investment Research.


Kapitall's by Ryan Horch. and Rebecca Lipman do not own any of the shares mentioned above. Ratings sources from Reuters

The Motley Fool owns shares of LinkedIn, Cisco Systems, salesforce.com, and Under Armour. Motley Fool newsletter services have recommended buying shares of LinkedIn, salesforce.com, and Under Armour. Motley Fool newsletter services have recommended creating a bear put spread position in salesforce.com. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1903749, ~/Articles/ArticleHandler.aspx, 8/28/2014 11:49:06 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement